Multiple human coagulation and anticoagulation factors

Multiple human coagulation and anticoagulation factors refers to a group of Vitamin K-dependent proteins that are essential for the regulation of blood clotting and the maintenance of hemostasis. This group includes the pro-coagulant factors II (prothrombin), VII, IX, and X, as well as the anti-coagulant proteins C and S. These proteins require a unique post-translational modification called gamma-carboxylation, which is mediated by Vitamin K, to become biologically active and bind to phospholipid membranes at the site of vascular injury. Therapeutic agents targeting this group, primarily Vitamin K antagonists like warfarin, act by inhibiting the recycling of Vitamin K, leading to the production of dysfunctional factors and a systemic anticoagulant effect. This mechanism is a cornerstone of therapy for preventing and treating thromboembolic disorders such as deep vein thrombosis, pulmonary embolism, and stroke in patients with atrial fibrillation.

Other names

Vitamin K-dependent clotting factorsVitamin K-dependent proteinsProthrombin complex factorsFactors II, VII, IX, X, Protein C, and Protein S

Vitamin K antagonists inhibit the enzyme Vitamin K epoxide reductase (VKORC1), which is responsible for converting Vitamin K epoxide back to its reduced form (Vitamin K hydroquinone). Reduced Vitamin K is an essential cofactor for the gamma-glutamyl carboxylase enzyme, which performs post-translational gamma-carboxylation of glutamic acid residues on Factors II, VII, IX, X, and Proteins C and S. Without this modification, these factors cannot bind calcium or phospholipid membranes, rendering them biologically inactive.